Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Thymectomy
5 evidence topics · 5 sources
Thymectomy in nonthymomatous AChR antibody-positive disease: 2020 consensus update
“In nonthymomatous, generalized MG patients with AChR-Ab, aged 18–50 years, thymectomy should be considered early in the disease to improve clinical outcomes and to minimize immunotherapy requirements and the need for hospitalizations for disease exacerbations (median 9, range 2–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymectomy should be strongly considered in patients with AChR-Ab+ generalized MG if they fail to respond to an initial adequate trial of immunotherapy or have intolerable side effects from that therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current evidence does not support an indication for thymectomy in patients with MuSK, low-density lipoprotein receptor–related protein 4, or agrin antibodies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGTX randomized trial: 3-year results
“A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MGTX extension: 5-year results
“Of 111 subjects who completed the 3-year MGTX trial, 68 (61%) entered the extension study between September 1, 2009 and August 26, 2015 (33 prednisone alone; 35 prednisone plus thymectomy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years, patients randomised to thymectomy plus prednisone continued to demonstrate improved clinical status compared to patients in the prednisone alone group based on time-weighted average QMG (5.47±3.87 vs. 9.34±5.08; 95% CI for the difference 0.71–7.04; p=0.0007) and lower average alternate-day prednisone requirements (24 mg±21 mg vs. 48±29 mg; 95% CI for the difference 12–36 mg; p=0.0002). The proportion of patients requiring hospitalisation for MG exacerbation (6% vs. 30%; 95% CI for the difference 7.1–42.1%; p=0.0105) was lower in the thymectomy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AAN practice advisory on thymectomy
“For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Timing of thymectomy by age: Nordic guidance
“In patients with non‐thymoma, generalized MG, AChR antibodies, and age below 50 years, thymectomy should be performed within 4 months from diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with non‐thymoma generalized MG, AChR antibodies, and age 50–65 years, early thymectomy should be considered if minimal manifestations are not reached, or the patient has substantial side effects from treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minimally invasive techniques are preferred with fewer perioperative complications, shorter hospitalization time, and minimal scars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote